Your Shopping Cart Is Empty
| Report Code: A01787 | Jul 2021 | Pages: 300 | ||
| Tables: 131 | Charts: 68 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Digital Therapeutics Market
Request Now !The global digital therapeutics market size was valued at $3,845.74 Million in 2021, and is projected to reach $22,601.97 Million by 2031, registering a CAGR of 19.4% from 2022 to 2031.Digital therapy provides patients with evidence-based therapeutic interventions. It is provided through software and devices to prevent manage or treat medical conditions. The digital therapy software application can be used alone or in conjunction with another device, medication, or therapy to provide patient care and health outcomes. The design, clinical validation, usability, and data security of digital therapeutics are all based on cutting-edge technology at best practices. These products are reviewed and approved by regulatory agencies prior to use. In addition, digital therapies provide patients, healthcare providers, and payers with smart, accessible tools to treat a wide range of conditions through interventions such as high quality, safe and effective evidence-based cards.
The digital therapeutics market is expected to be positively impacted by the COVID-19 pandemic, owing to awareness regarding importance of digital health, rise in prevalence of mental illness, and increase in rate of drug abuse globally. Moreover, during this pandemic, people had to stay at home, which led to less physical activity, unhealthy lifestyle, and mental stress and, in turn, increasing the prevalence of chronic diseases. Hence, there is a rise in demand for DTx devices and software across the globe. Recent easing of regulatory approvals for DTx based treatments further drives the growth of the market. For instance, the U.S. FDA issued temporary guidance for Pear Therapeutics products for mental health amidst the COVID-19 pandemic. Furthermore, it suggests that regulatory agencies acknowledge the importance of digital therapeutics products.
Digital therapeutics such as Pear-001, CT-152, MR-001, Bluestar and Propeller Health are some of the products offered by the topmost companies. Digital therapeutics solutions help improve medication adherence with personalized incentives to encourage long-term behavior change in patients and for people with chronic conditions like diabetes and COPD, digital therapeutics can play an important role in the treatment.
The increase in the use of smartphones and tablets, along with healthcare applications, the rise in need to control healthcare costs, significant benefits to the entire process healthcare and surge in incidence of chronic diseases fuel the growth of the global digital therapeutics market. Rise in the incidence of preventable chronic diseases, and increase in government funding on healthcare are the major factors expected to accelerate the market growth. Also emerging markets are predicted to provide significant growth opportunities for companies in the coming years. Besides this, strong potential products expected to be launched during the forecast period will also be profitable to the market players. Factors such as the cost effectiveness of digital health technologies for providers and patients, and the rise in need for integrated health systems and patient-centered care are expected to drive market growth during the forecast period.
However, lack of understanding about digital therapies in developing countries and patient data privacy issues are hindering the growth of the market. The developers or manufacturers of digital therapeutics do not guarantee the security of patient data. Consumers fear that these apps will not be able to protect the confidentiality of their health data. Fears about the privacy of patients are hindering the adoption of digital therapeutics. In addition, the fear that the data will be compromised or that the technology will expose it to unwanted personal surveillance further hinders the growth of the digital therapeutics market.
Digital therapeutics has become an important treatment option for patients with medical conditions, mainly due to personalized treatment programs and different strategies adopted by key players. The strategies adopted by the key players mainly include the acquisition, product approval, product launch, and partnership. Furthermore, the rise of chronic diseases such as heart disease, diabetes, anxiety disorders and others has prompted major players in the market to pursue digital treatments. Currently, a number of manufacturers are developing products to treat anxiety disorders, and several products are being developed at different stages of development which serves as the great opportunity for the growth of the market.
In addition, the COVID-19 has a greater impact on the digital therapeutics market. There is a huge potential in the digital therapeutics market and investors are investing more in this industry. Investments in digital-therapeutics companies in the U.S. have increased, on an average by 40% a year over the past seven years. Furthermore, billions of dollars have been invested in digital health in the past decade and the market is growing at a very good pace. As per the Rock Health report, the U.S. digital health sector had its second-highest year of investment of $14.1 billion in 2020.
The digital therapeutics market, which is a subset of digital health, has also gained significant traction in the recent years. The COVID-19 pandemic disrupted the healthcare system all over the world and as health responses to the pandemic are strengthened, a need for a substantial shift to apps and hardware capable for lifestyle enhancement and medical intervention, with potentially life-saving functionalities has emerged.
The digital therapeutics market is expected to be positively impacted by the COVID-19 pandemic, owing to awareness regarding importance of digital health, rise in prevalence of mental illness, and increase in rate of drug abuse globally. Moreover, during this pandemic, people had to stay at home, which led to less physical activity, unhealthy lifestyle, and mental stress and, in turn, increasing the prevalence of chronic diseases. Hence, there is a rise in demand for DTx devices and software across the globe. Recent easing of regulatory approvals for DTx based treatments further drives the growth of the market. For instance, the U.S. FDA issued temporary guidance for Pear Therapeutics products for mental health amidst the COVID-19 pandemic. Furthermore, it suggests that regulatory agencies acknowledge the importance of digital therapeutics products.
The digital therapeutics market is segmented into product, sales channel, application, and region. On the basis of product segment, the market is categorized into software and devices. On the basis of sales channel, the market is bifurcated into business-to-business and business-to-consumers. On the basis of applications the market is segmented into diabetes, obesity, cardiovascular disease (CVD), diseases of the actually central nervous system (CNS), respiratory conditions, quitting smoking, gastrointestinal problems, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Saudi Arabia, South Africa, and rest of LAMEA).
By product, the software segment is the largest and the fastest growing segment, which dominated the market in 2021, and is expected to continue this trend during the forecast period owing to perpetual improvements happening in device software.
By sales channel, the business-to-consumers segment is the largest and the fastest growing segment which exhibited the highest growth in 2021, and is expected to continue this trend during the forecast period.
North America accounted for a majority of the digital therapeutics market share in 2021, and is anticipated to remain dominant during the forecast period. Europe is the fastest growing market. This is attributed to increase in the usage of smartphones and digital devices, increasing chronic diseases, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in digitalization, unmet medical demands, and increase in investments in the healthcare sector in the region.
The key players operating in the global digital therapeutics market are 2MORROW Inc., Akili Interactive Labs Inc., Click Therapeutics Inc., Fitbit Inc. (Twine Health, Inc.), Happify Inc., Kaia Health, Livongo Health Inc., Medtronic Plc., Omada Health Inc., Pear Therapeutics Inc., Proteus Digital Health Inc., Resmed Inc. (Propeller Health), Voluntis Inc., Welldoc Inc.
Key Benefits For Stakeholders
Digital Therapeutics Market Report Highlights
| Aspects | Details |
|---|---|
| By product |
|
| By sales channel |
|
| By Region |
|
| Key Market Players | Akili Interactive Labs, Inc., Happify, Inc., Medtronic Plc., 2MORROW, Inc., Livongo Health, Inc., Omada Health, Inc., Proteus Digital Health, Inc., Fitbit, Inc. (Twine Health, Inc.), Click Therapeutics, Inc., Welldoc, Inc, Pear Therapeutics, Inc., Resmed, Inc. (Propeller Health), Kaia Health, Voluntis, Inc. |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Increase in adoption of smartphones and tablets, coupled with healthcare apps
3.3.1.2.Rise in need to control healthcare costs
3.3.1.3.Rise in incidences of chronic diseases
3.3.1.4.Significant benefits to the entire healthcare continuum
3.3.2.Restraints
3.3.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.3.2.2.Patient data privacy concerns
3.3.3.Opportunity
3.3.3.1.Extensive product pipeline
3.4.Impact analysis of COVID-19 on the digital therapeutics market
3.5.Impact of government regulations on global digital therapeutics market
3.5.1.U.S. FDA’s premarket clearance and approval requirements
3.5.2.European Union premarket clearance and approval requirements
3.5.3.Japan premarket clearance and approval requirements
3.6.Key digital technologies for digital therapeutics
3.6.1.Mobile health (mHealth)
3.6.2.Personalized healthcare
3.6.3.Digital Cognitive Behavior Therapy (CBT)
3.6.4.Wearable devices and sensors
3.7.Necessary human resources required for digital therapeutics development
3.8.Usage of patient data acquired from digital therapeutics
3.8.1.Types of personal information that are collected by DTx companies
CHAPTER 4:DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market size and forecast
4.9.3.Market analysis, by country
CHAPTER 5:DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Devices
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Business-to-consumers
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
CHAPTER 7:DIGITAL THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America digital therapeutics market, by country
7.2.3.North America digital therapeutics market, by application
7.2.4.North America digital therapeutics market, by product type
7.2.5.North America digital therapeutics market, by sales channel
7.2.5.1.U.S.
7.2.5.1.1.U.S. digital therapeutics market, by application
7.2.5.1.2.U.S digital therapeutics market, by product type
7.2.5.1.3.U.S. digital therapeutics market, by sales channel
7.2.5.2.Canada
7.2.5.2.1.Canada digital therapeutics market, by application
7.2.5.2.2.Canada digital therapeutics market, by product type
7.2.5.2.3.Canada digital therapeutics market, by sales channel
7.2.5.3.Mexico.
7.2.5.3.1.Mexico digital therapeutics market, by application
7.2.5.3.2.Mexico digital therapeutics market, by product type
7.2.5.3.3.Mexico digital therapeutics market, by sales channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe digital therapeutics market, by country
7.3.3.Europe digital therapeutics market, by application
7.3.4.Europe digital therapeutics market, by product type
7.3.5.Europe digital therapeutics market, by sales channel
7.3.5.1.UK
7.3.5.1.1.UK digital therapeutics market, by application
7.3.5.1.2.UK digital therapeutics market, by product type
7.3.5.1.3.UK digital therapeutics market, by sales channel
7.3.5.2.Germany.
7.3.5.2.1.Germany digital therapeutics market, by application
7.3.5.2.2.Germany digital therapeutics market, by product type
7.3.5.2.3.Germany digital therapeutics market, by sales channel
7.3.5.3.France.
7.3.5.3.1.France digital therapeutics market, by application
7.3.5.3.2.France digital therapeutics market, by product type
7.3.5.3.3.France digital therapeutics market, by sales channel
7.3.5.4.Italy
7.3.5.4.1.Italy digital therapeutics market, by application
7.3.5.4.2.Italy digital therapeutics market, by product type
7.3.5.4.3.Italy digital therapeutics market, by sales channel
7.3.5.5.Spain
7.3.5.5.1.Spain digital therapeutics market, by application
7.3.5.5.2.Spain digital therapeutics market, by product type
7.3.5.5.3.Spain digital therapeutics market, by sales channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe digital therapeutics market, by application
7.3.5.6.2.Rest of Europe digital therapeutics market, by product type
7.3.5.6.3.Rest of Europe digital therapeutics market, by sales channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific digital therapeutics market, by country
7.4.3.Asia-Pacific digital therapeutics market, by application
7.4.4.Asia-Pacific digital therapeutics market, by product type
7.4.5.Asia-Pacific digital therapeutics market, by sales channel
7.4.5.1.Japan
7.4.5.1.1.Japan digital therapeutics market, by application
7.4.5.1.2.Japan digital therapeutics market, by product type
7.4.5.1.3.Japan digital therapeutics market, by sales channel
7.4.5.2.China
7.4.5.2.1.China digital therapeutics market, by application
7.4.5.2.2.China digital therapeutics market, by product type
7.4.5.2.3.China digital therapeutics market, by sales channel
7.4.5.3.Australia
7.4.5.3.1.Australia digital therapeutics market, by application
7.4.5.3.2.Australia digital therapeutics market, by product type
7.4.5.3.3.Australia digital therapeutics market, by sales channel
7.4.5.4.India
7.4.5.4.1.India digital therapeutics market, by application
7.4.5.4.2.India digital therapeutics market, by product type
7.4.5.4.3.India digital therapeutics market, by sales channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea digital therapeutics market, by application
7.4.5.5.2.South Korea digital therapeutics market, by product type
7.4.5.5.3.South Korea digital therapeutics market, by sales channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific digital therapeutics market, by application
7.4.5.6.2.Rest of Asia-Pacific digital therapeutics market, by product type
7.4.5.6.3.Rest of Asia-Pacific digital therapeutics market, by sales channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA digital therapeutics market, by country
7.5.3.LAMEA digital therapeutics market, by application
7.5.4.LAMEA digital therapeutics market, by product type
7.5.5.LAMEA digital therapeutics market, by sales channel
7.5.5.1.Brazil
7.5.5.1.1.Brazil digital therapeutics market, by application
7.5.5.1.2.Brazil digital therapeutics market, by product type
7.5.5.1.3.Brazil digital therapeutics market, by sales channel
7.5.5.2.Turkey
7.5.5.2.1.Turkey digital therapeutics market, by application
7.5.5.2.2.Turkey digital therapeutics market, by product type
7.5.5.2.3.Turkey digital therapeutics market, by sales channel
7.5.5.3.Saudi Arabia
7.5.5.3.1.Saudi Arabia digital therapeutics market, by application
7.5.5.3.2.Saudi Arabia digital therapeutics market, by product type
7.5.5.3.3.Saudi Arabia digital therapeutics market, by sales channel
7.5.5.4.South Africa
7.5.5.4.1.South Africa digital therapeutics market, by application
7.5.5.4.2.South Africa digital therapeutics market, by product type
7.5.5.4.3.South Africa digital therapeutics market, by sales channel
7.5.5.5.Rest of LAMEA
7.5.5.5.1.Rest of LAMEA digital therapeutics market, by application
7.5.5.5.2.Rest of LAMEA digital therapeutics market, by product type
7.5.5.5.3.Rest of LAMEA digital therapeutics market, by sales channel
CHAPTER 8:COMPETITION LANDSCAPE
8.1.Top winning strategies
8.2.Product mapping
8.3.Competitive dashboard
8.4.Competitive heatmap
8.5.Key developments
8.5.1.Product Launch
8.5.2.Product Approval
8.5.3.Agreement
8.5.4.Collaboration
8.5.5.Acquisitions
8.5.6.Business Expansion
8.5.7.Partnership
8.6.Top player positioning, 2021
CHAPTER 9:COMPANY PROFILES
9.1.2MORROW, INC.
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments
9.2.AKILI INTERACTIVE LABS, INC.
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Product portfolio
9.2.4.Key strategic moves and developments
9.3.CLICK THERAPEUTICS, INC.
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Key strategic moves and developments
9.4.FITBIT, INC. (TWINE HEALTH, INC.)
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Product portfolio
9.4.4.Business performance
9.4.5.Key strategic moves and developments
9.5.HAPPIFY, INC.
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Product portfolio
9.5.4.Key strategic moves and developments
9.6.KAIA HEALTH
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Product portfolio
9.6.4.Key strategic moves and developments
9.7.MEDTRONIC PLC.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments
9.8.OMADA HEALTH, INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Key strategic moves and developments
9.9.PEAR THERAPEUTICS, INC.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Product portfolio
9.9.4.Key strategic moves and developments
9.10.PROTEUS DIGITAL HEALTH, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Key strategic moves and developments
9.11.RESMED, INC. (PROPELLER HEALTH)
9.11.1.Company overview
9.11.2.Company snapshot
9.11.3.Operating business segments
9.11.4.Product portfolio
9.11.5.Business performance
9.11.6.Key strategic moves and developments
9.12.TELADOC HEALTH, INC.(LIVONGO HEALTH)
9.12.1.Company overview
9.12.2.Company snapshot
9.12.3.Product portfolio
9.12.4.Business performance
9.12.5.Key strategic moves and developments
9.13.VOLUNTIS, INC.
9.13.1.Company overview
9.13.2.Company snapshot
9.13.3.Operating business segments
9.13.4.Product portfolio
9.13.5.Business performance
9.13.6.Key strategic moves and developments
9.14.WELLDOC, INC.
9.14.1.Company overview
9.14.2.Company snapshot
9.14.3.Operating business segments
9.14.4.Product portfolio
9.14.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.DIGITAL THERAPEUTIC PRODUCT LIST
TABLE 02.FDA CLASSIFICATION OF MEDICAL DEVICES
TABLE 03.DIGITAL SKILLS REQUIRED FOR EMPLOYEES DEDICATED FOR DTX DEVELOPMENTS
TABLE 04.RANGE OF NUMBER OF EMPLOYEES WITH DIGITAL SKILLS DEDICATED FOR DIGITAL THERAPEUTICS DEVELOPMENTS, BY COMPANY
TABLE 05.GLOBAL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 06.DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2021-2031 ($MILLION)
TABLE 07.DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2021-2031 ($MILLION)
TABLE 08.DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2031 ($MILLION)
TABLE 09.DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY REGION, 2021-2031 ($MILLION)
TABLE 10.SMART PILLS FOR CAPSULE ENDOSCOPY, DRUG DELIVERY, AND PATIENT MONITORING AVAILABLE IN THE MARKET
TABLE 11.DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY REGION, 2021-2031 ($MILLION)
TABLE 12.DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021-2031 ($MILLION)
TABLE 13.DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2021-2031 ($MILLION)
TABLE 14.DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 15.GLOBAL DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 16.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 17.DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY REGION, 2021-2031 ($MILLION)
TABLE 18.DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY REGION, 2021-2031 ($MILLION)
TABLE 19.GLOBAL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 20.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2021-2031 ($MILLION)
TABLE 21.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY REGION, 2021-2031 ($MILLION)
TABLE 22.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2021-2031 ($MILLION)
TABLE 23.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY REGION, 2021-2031 ($MILLION)
TABLE 24.DIGITAL THERAPEUTICS MARKET REVENUE, BY REGION, 2021–2031 ($MILLION)
TABLE 25.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 26.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 27.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 28.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2031 ($MILLION)
TABLE 29.U.S. DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 30.U.S. DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 31.U.S. DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2031 ($MILLION)
TABLE 32.CANADA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 33.CANADA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 34.CANADA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2031 ($MILLION)
TABLE 35.MEXICO DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 36.MEXICO DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 37.MEXICO DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2031 ($MILLION)
TABLE 38.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 39.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 40.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 41.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2031 ($MILLION)
TABLE 42.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2031 ($MILLION)
TABLE 43.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021–2031 ($MILLION)
TABLE 44.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031($MILLION)
TABLE 45.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 47.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 48.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031($MILLION)
TABLE 49.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 50.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL2021-2031 ($MILLION)
TABLE 51.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 52.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 53.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 54.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 55.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 56.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 57.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 58.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 59.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 60.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 61.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 62.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 63.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 64.JAPAN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65.JAPAN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 66.JAPAN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 67.CHINA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 68.CHINA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 69.CHINA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 70.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 72.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 73.INDIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74.INDIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 75.INDIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 76.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 77.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 78.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 79.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 81.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 82.LAMEA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 83.LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84.LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 85.LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 86.BRAZIL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 87.BRAZIL DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 88.BRAZIL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 89.TURKEY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 90.TURKEY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 91.TURKEY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 92.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 93.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 94.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 95.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 96.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 97.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 98.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 99.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 100.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
TABLE 101.2MORROW: COMPANY SNAPSHOT
TABLE 102.2MORROW: PRODUCT PORTFOLIO
TABLE 103.AKILI: COMPANY SNAPSHOT
TABLE 104.AKILI: PRODUCT PORTFOLIO
TABLE 105.CLICK THERAPEUTICS: COMPANY SNAPSHOT
TABLE 106.CLICK THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 107.FITBIT: COMPANY SNAPSHOT
TABLE 108.FITBIT: PRODUCT PORTFOLIO
TABLE 109.HAPPIFY: COMPANY SNAPSHOT
TABLE 110.HAPPIFY: PRODUCT PORTFOLIO
TABLE 111.KAIA: COMPANY SNAPSHOT
TABLE 112.KAIA: PRODUCT PORTFOLIO
TABLE 113.MEDTRONIC: COMPANY SNAPSHOT
TABLE 114.MEDTRONIC: OPERATING SEGMENTS
TABLE 115.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 116.OMADA: COMPANY SNAPSHOT
TABLE 117.OMADA: PRODUCT PORTFOLIO
TABLE 118.PEAR: COMPANY SNAPSHOT
TABLE 119.PEAR: PRODUCT PORTFOLIO
TABLE 120.PROTEUS: COMPANY SNAPSHOT
TABLE 121.PROTEUS: PRODUCT PORTFOLIO
TABLE 122.RESMED: COMPANY SNAPSHOT
TABLE 123.RESMED: OPERATING SEGMENTS
TABLE 124.RESMED: PRODUCT PORTFOLIO
TABLE 125.TELADOC: COMPANY SNAPSHOT
TABLE 126.TELADOC: PRODUCT PORTFOLIO
TABLE 127.VOLUNTIS: COMPANY SNAPSHOT
TABLE 128.VOLUNTIS: OPERATING SEGMENTS
TABLE 129.VOLUNTIS: PRODUCT PORTFOLIO
TABLE 130.WELLDOC: COMPANY SNAPSHOT
TABLE 131.WELLDOC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTION
FIGURE 06.MODERATE THREAT OF NEW ENTRANT
FIGURE 07.MODERATE COMPETITIVE RIVALRY
FIGURE 08.GLOBAL DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 09.DIGITAL THERAPEUTICS MARKET, BY APPLICATION
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2021 & 2031 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2021 & 2031 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021 & 2031 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CNS DISEASES, BY COUNTRY, 2021 & 2031 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2021 & 2031 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2021 & 2031 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2021 & 2031 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021 & 2031 (%)
FIGURE 18.DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2021 & 2031 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2021 & 2031 (%)
FIGURE 21.DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 22.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2021-2031 ($MILLION)
FIGURE 23.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2021-2031 ($MILLION)
FIGURE 24.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2021-2031 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF BUSINESS-TO-BUSINESS MARKET, BY COUNTRY 2021 & 2031 ($MILLION)
FIGURE 26.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2021-2031 ($MILLION)
FIGURE 27.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2021-2031 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF BUSINESS-TO-CONSUMERS, BY COUNTRY 2021 & 2031 ($MILLION)
FIGURE 29.U.S. DIGITAL THERAPEUTICS MARKET, 2021–2031 ($MILLION)
FIGURE 30.CANADA. DIGITAL THERAPEUTICS MARKET, 2021–2031 ($MILLION)
FIGURE 31.MEXICO DIGITAL THERAPEUTICS MARKET, 2021–2031 ($MILLION)
FIGURE 32.UK DIGITAL THERAPEUTICS MARKET, 2021–2031 ($MILLION)
FIGURE 33.GERMANY DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 34.FRANCE DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 35.ITALY DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 36.SPAIN DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 37.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 38.JAPAN DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 39.CHINA DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 40.AUSTRALIA DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 41.INDIA DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 42.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 43.REST OF ASIA PACIFIC DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 44.BRAZIL DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 45.TURKEY DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 46.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, 2021-2031($MILLION)
FIGURE 47.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, 2021-2031($MILLION)
FIGURE 48.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, 2021-2031 ($MILLION)
FIGURE 49.TOP WINNING STRATEGIES, BY YEAR, 2019–2022
FIGURE 50.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2022 ( % )
FIGURE 51.TOP WINNING STRATEGIES, BY COMPANY, 2019–2022
FIGURE 52.PRODUCT MAPPING OF TOP 14 KEY PLAYERS
FIGURE 53.COMPETITIVE DASHBOARD OF TOP 14 KEY PLAYERS
FIGURE 54.COMPETITIVE HEATMAP OF TOP 14 KEY PLAYERS
FIGURE 55.TOP PLAYER POSITIONING, 2021
FIGURE 56.FITBIT: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.FITBIT: NET SALES, BY REGION, 2019 (%)
FIGURE 58.MEDTRONIC: NET SALES, 2019-2021 ($MILLION)
FIGURE 59.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 60.MEDTRONIC: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 61.RESMED: NET SALES, 2019-2021 ($MILLION)
FIGURE 62.RESMED: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 63.RESMED: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 64.TELADOC: NET SALES, 2019-2021($MILLION)
FIGURE 65.TELADOC: REVENUE SHARE, BY REGION, 2021(%)
FIGURE 66.VOLUNTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 67.VOLUNTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 68.VOLUNTIS: REVENUE SHARE, BY REGION, 2020 (%)
Digital Therapeutics Market
This section provides the opinions of the top level CXOs in the digital therapeutics market. According to the insights of CXOs, the field of digital therapeutics is still young and has gained significant attention over the years. The digital therapeutics market has gained the interest of healthcare providers, patients, and medical practitioners, owing to several benefits offered by these devices to reduce healthcare expenditure, improve patient & doctor communication, and manage patient health efficiently. There has been remarkable technological advancements in development of novel digital therapeutics applications to provide advanced management options for chronic disease patients and to maintain healthy lifestyles. As the market is saturated and is growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market.
According to the perspectives of CXOs of leading companies in the market, significant advancements in the applications of digital therapeutic products with increase in clinically backed researches and advanced hardware and software are projected to increase the usage rate of digital therapeutics globally. Presently, rapid adoption of digital therapeutics is witnessed around the globe for wellness management such as fitness, diet & nutrition, diabetes, obesity, respiratory disorder, and lifestyle & stress management.
North America is expected to dominate in terms of revenue, owing to rapid rise in incidences of chronic illness, high adoption rate of digital therapeutics, robust R&D infrastructure for life science researches, presence of key players, and advancements in healthcare investments. Europe was the second largest contributor to the market in 2021, due to the continuous government support for pharmaceutical and R&D, increase in public–private investments, and rise in number of research activities in the healthcare sector for improved and efficient treatment. In addition, abundance of pipeline products is anticipated to drive the market growth.
A. The total market value of digital therapeutics market is $3,845.74 million in 2021.
A. The forecast period for digital therapeutics market is 2022 to 2031
A. The market value of digital therapeutics market in 2022 is $4,598.35 million.
A. The base year is 2021 in digital therapeutics market
A. Top companies such as 2morrow Inc., Akili interactive labs, Inc., Click therapeutics, Inc., Fitbit, Inc., Kaia health, Livongo health, Inc., Medtronic Plc., Omada health, Pear therapeutics, Inc., Proteus digital health, Inc., Resmed, Inc, Voluntis, Inc and Welldoc, Inc. held a high market position in 2021.
A. Software segment dominated the global market in 2021, and expected to continue this trend throughout the forecast period due the advancements and digitalization and adoption of the smartphones and various devices.
A. Increase in adoption of smartphones and tablets, coupled with healthcare apps, rise in need to control healthcare costs, rise in incidences of chronic diseases and significant benefits to the entire healthcare continuum are the key growth factor for the market.
A. North America is projected to account for a major share of the digital therapeutics market during the forecast period. U.S. dominated the North America digital therapeutics market owing to increased advancements in the digital treatment. Europe is expected to be the fastes growing market in the froecast period.
Start reading instantly.
This Report and over 67,585+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report